Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 6/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.38 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376792 | 0.90 | IRAK4 (0.40) | IGF1RIRAK4CDK2MAPK10MAPK8 | |
| SCHEMBL3230923 | 0.80 | GFER (0.45) | IGF1RIRAK4CDK2MAPK10MAPK8 | |
| SCHEMBL376384 | 0.78 | HCRTR2 (0.36) | HCRTR2 | |
| SCHEMBL376301 | 0.77 | PIK3CD (0.42) | IGF1RIRAK4CDK2MAPK10MAPK8 | |
| SCHEMBL376238 | 0.77 | CDK2 (0.38) | IGF1RIRAK4CDK2MAPK10MAPK8 | |
| SCHEMBL12553187 | 0.74 | IRAK4 (0.41) | IGF1RIRAK4CDK2MAPK10MAPK8 | |
| SCHEMBL376071 | 0.72 | MAPK8 (0.37) | MAPK10MAPK8MAPK9HCRTR2 | |
| SCHEMBL376803 | 0.72 | IRAK4 (0.66) | IRAK4MAPK8PIK3CA | |
| SCHEMBL10239859 | 0.72 | IRAK4 (0.64) | IRAK4MAPK8 | |
| SCHEMBL376265 | 0.71 | IRAK4 (0.34) | IGF1RIRAK4CDK2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | IGF1R 688/4885IRAK4 816/4885CDK2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.